Log in

Acura Pharmaceuticals Stock Forecast, Price & News

-0.01 (-3.94 %)
(As of 12/4/2020 12:00 AM ET)
Today's Range
Now: $0.24
50-Day Range
MA: $0.25
52-Week Range
Now: $0.24
Volume3,944 shs
Average Volume9,767 shs
Market Capitalization$5.28 million
P/E RatioN/A
Dividend YieldN/A
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was founded in 1935 and is based in Palatine, Illinois.
Acura Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.56 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolOTCMKTS:ACUR
Previous SymbolNASDAQ:ACUR



Sales & Book Value

Annual Sales$2.66 million
Book Value($0.26) per share



Market Cap$5.28 million
Next Earnings Date3/29/2021 (Estimated)
OptionableNot Optionable
-0.01 (-3.94 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ACUR News and Ratings via Email

Sign-up to receive the latest news and ratings for ACUR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Acura Pharmaceuticals (OTCMKTS:ACUR) Frequently Asked Questions

How has Acura Pharmaceuticals' stock price been impacted by COVID-19?

Acura Pharmaceuticals' stock was trading at $0.34 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ACUR shares have decreased by 28.2% and is now trading at $0.2441.
View which stocks have been most impacted by COVID-19

What stocks does MarketBeat like better than Acura Pharmaceuticals?

Wall Street analysts have given Acura Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Acura Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Acura Pharmaceuticals' next earnings date?

Acura Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 29th 2021.
View our earnings forecast for Acura Pharmaceuticals

How were Acura Pharmaceuticals' earnings last quarter?

Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) announced its earnings results on Friday, February, 28th. The specialty pharmaceutical company reported $0.00 earnings per share for the quarter. The specialty pharmaceutical company had revenue of $1.32 million for the quarter. Acura Pharmaceuticals had a negative return on equity of 1.36% and a negative net margin of 19.89%.
View Acura Pharmaceuticals' earnings history

Are investors shorting Acura Pharmaceuticals?

Acura Pharmaceuticals saw a increase in short interest in November. As of November 15th, there was short interest totaling 30,300 shares, an increase of 154.6% from the October 31st total of 11,900 shares. Based on an average trading volume of 19,400 shares, the days-to-cover ratio is currently 1.6 days.
View Acura Pharmaceuticals' Short Interest

Who are some of Acura Pharmaceuticals' key competitors?

What other stocks do shareholders of Acura Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acura Pharmaceuticals investors own include Denali Therapeutics (DNLI), Adamis Pharmaceuticals (ADMP), Ekso Bionics (EKSO), VIVUS (VVUS), Fulcrum Therapeutics (FULC), (GBSN) (GBSN), Trevena (TRVN), AcelRx Pharmaceuticals (ACRX), Allena Pharmaceuticals (ALNA) and Advanced Micro Devices (AMD).

Who are Acura Pharmaceuticals' key executives?

Acura Pharmaceuticals' management team includes the following people:
  • Mr. Robert B. Jones, CEO, Pres & Director (Age 61, Pay $123k)
  • Mr. Peter A. Clemens, Sr. VP, CFO & Sec. (Age 67, Pay $164k)
  • Dr. Albert W. Brzeczko, VP of Pharmaceutical Sciences of Acura Pharmaceutical Technologies, Inc. (Age 63, Pay $180k)
  • Mr. James F. Emigh, VP of Corp. Devel. (Age 64)
  • Mr. Robert A. Seiser CPA, Ph.D., VP, Treasurer & Corp. Controller (Age 56)

What is Acura Pharmaceuticals' stock symbol?

Acura Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ACUR."

How do I buy shares of Acura Pharmaceuticals?

Shares of ACUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Acura Pharmaceuticals' stock price today?

One share of ACUR stock can currently be purchased for approximately $0.24.

How big of a company is Acura Pharmaceuticals?

Acura Pharmaceuticals has a market capitalization of $5.28 million and generates $2.66 million in revenue each year. Acura Pharmaceuticals employs 12 workers across the globe.

What is Acura Pharmaceuticals' official website?

The official website for Acura Pharmaceuticals is www.acurapharm.com.

How can I contact Acura Pharmaceuticals?

Acura Pharmaceuticals' mailing address is 616 N. NORTH COURT SUITE 120, PALATINE IL, 60067. The specialty pharmaceutical company can be reached via phone at 847-705-7709 or via email at [email protected]

This page was last updated on 12/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.